

Cell Line Data Sheet for CHLA-132

Disease: Neuroblastoma
Phase of Therapy: Progressive Disease
Treatment: N/A
Disease Stage: 4
Gender: Female
Age at diagnosis: N/A
Race: N/A
Age at sample collection: N/A
Source of Culture: Bone Marrow
Primary Tumor Site: N/A
Date Established: May 1993

MYCN Patient: Non-amplified
MYCN Cell line: N/A
THmRNA: Expressed
p53 functionality: N/A
Telomere Mechanism: N/A
ALK: N/A
RNAseq: N/A
WES: N/A

Growth Conditions: Please see Protocols section at <https://www.cccells.org/protocols.php>
 5% CO₂, 20% O₂, 37.0°C

Media Formulation: Please see Protocols section at <https://www.cccells.org/protocols.php>
 Cells are grown in a base medium of Iscove's Modified Dulbecco's Medium plus the following supplements (to a final concentration): 20% Fetal Bovine Serum, 4mM L-Glutamine, 1X ITS (5 µg/mL insulin, 5 µg/mL transferrin, 5 ng/mL selenous acid)

Doubling Time: N/A
Growth Properties: N/A

STR Profile: May be obtained at <https://strdb.cccells.org/>
Notes: None

All COG Repository cell lines are antibiotic-free, mycoplasma-free, and cryopreserved in 50% FBS / 7.5% DMSO. Each vial label contains the cell line name, passage number, total viable cell count (usually 5-10e6), the overall cell viability, and date frozen. All cell lines are validated with original patient sample by STR analysis



Cell Line Data Sheet for CHLA-132

Cell Line Name: CHLA-132

References:

1. B. Koneru, G. Lopez, A170:E170 A. Farooqi, K. L. Conkrite, T. H. Nguyen, S. J. Macha, A. Modi, J. L. Rokita, E. Urias, A. Hindle, H. Davidson, K. McCoy, J. Nance, V. Yazdani, M. S. Irwin, S. Yang, D. A. Wheeler, J. M. Maris, S. J. Diskin, C. P. Reynolds, Telomere Maintenance Mechanisms Define Clinical Outcome in High-Risk Neuroblastoma. *Cancer Res.* 2020;80:2663-2675." PMID 32291317
<https://cancerres.aacrjournals.org/content/80/12/2663.long>



Cell Line Data Sheet for CHLA-132

No images available